Shiro Suzuki Kiyosumi Shibata Fumitaka Kikkawa Tetsuya Nakatsura
10.4161/hv.27217
Hum Vaccin Immunother
2014;10(2):338-43.
glypican-3 clinical response ovarian clear cell carcinoma peptide vaccine refractory disease
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/24252799/
Carcinoma / therapy Glypicans / immunology Immunotherapy / methods Ovarian Neoplasms / therapy Vaccines, Subunit / immunology Vaccines, Subunit / therapeutic use
Carcinoma / therapy Glypicans / immunology Immunotherapy / methods Ovarian Neoplasms / therapy Vaccines, Subunit / immunology Vaccines, Subunit / therapeutic use Case Reports Clinical Trial, Phase II Adjuvants, Immunologic / administration & dosage Adult Aged Female Freund's Adjuvant / administration & dosage Glypicans / genetics Humans Injections, Intradermal Recurrence Treatment Outcome Adjuvants, Immunologic GPC3 protein, human Glypicans Vaccines, Subunit Freund's Adjuvant
PMC4185885
24252799
Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports
2014